Literature DB >> 24845508

Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.

Murugan Subathra1, Ponsekaran Santhakumar, Mangamoori Lakshmi Narasu, Syed Sultan Beevi, Sunil K Lal.   

Abstract

Avian influenza has raised many apprehension in the recent years because of its potential transmitability to humans. With the increasing emergence of drug-resistant avian influenza strains, development of potential vaccines are imperative to manage this disease. Two structural antigens, haemagglutinin and neuraminidase, have been the target candidates for the development of subunit vaccine against influenza. In an effort to develop a faster and economically beneficial vaccine, the neuraminidase gene of a highly pathogenic avian influenza isolate was cloned and expressed in the methylotrophic yeast Pichia pastoris. The recombinant neuraminidase (rNA) antigen was purified, and its bioactivity was analysed. The rNA was found to be functional, as determined by the neuraminidase assay. Four groups of mice were immunized with different concentrations of purified rNA antigen, which were adjuvanted with aluminium hydroxide. The immune response against rNA was analysed by enzyme-linked immunosorbent assay (ELISA) and neuraminidase inhibition assay. The mice groups immunized with 25 (mu) g and 10 (mu) g of antigen had a significant immune response against rNA. This method can be utilized for faster and cost-effective development of vaccines for a circulating and newer strain of avian influenza, and would aid in combating the disease in a pandemic situation, in which production time matters greatly.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24845508     DOI: 10.1007/s12038-014-9422-3

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  37 in total

1.  Yeast expressed classical swine fever E2 subunit vaccine candidate provides complete protection against lethal challenge infection and prevents horizontal virus transmission.

Authors:  Guang-Jan Lin; Ming-Chung Deng; Zeng-Weng Chen; Ting-Yu Liu; Ching-Wei Wu; Chih-Yuan Cheng; Maw-Sheng Chien; Chienjin Huang
Journal:  Vaccine       Date:  2012-01-30       Impact factor: 3.641

Review 2.  Heterologous protein expression in the methylotrophic yeast Pichia pastoris.

Authors:  J L Cereghino; J M Cregg
Journal:  FEMS Microbiol Rev       Date:  2000-01       Impact factor: 16.408

3.  Expression, purification and characterization of low-glycosylation influenza neuraminidase in α-1,6-mannosyltransferase defective Pichia pastoris.

Authors:  Yi-Li Yang; Shao-Hong Chang; Xin Gong; Jun Wu; Bo Liu
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

4.  Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.

Authors:  F Fang; X Q Cai; H Y Chang; H D Wang; Z D Yang; Z Chen
Journal:  Acta Virol       Date:  2008       Impact factor: 1.162

5.  Recombinant neuraminidase vaccine protects against lethal influenza.

Authors:  T Deroo; W M Jou; W Fiers
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

Review 6.  From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.

Authors:  John M Wood; James S Robertson
Journal:  Nat Rev Microbiol       Date:  2004-10       Impact factor: 60.633

7.  Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin.

Authors:  S Kodihalli; J R Haynes; H L Robinson; R G Webster
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  NEW technologies for meeting the global demand for pandemic influenza vaccines.

Authors:  David S Fedson
Journal:  Biologicals       Date:  2008-08-19       Impact factor: 1.856

9.  Avian influenza A (H5N1) in 10 patients in Vietnam.

Authors:  Tinh Hien Tran; Thanh Liem Nguyen; Thi Dung Nguyen; Thi San Luong; Phuong Mai Pham; van Vinh Chau Nguyen; Thi Suu Pham; Cong Dong Vo; Thi Quynh Mai Le; Thi Thi Ngo; Bach Khoa Dao; Phuc Phat Le; Thanh Truong Nguyen; Thuy Long Hoang; Viet Tung Cao; Truong Giang Le; Dac Tho Nguyen; Hong Nga Le; Kim Tien Nguyen; Hoang San Le; Van Tuan Le; Dolecek Christiane; Tan Thanh Tran; de Jong Menno; Constance Schultsz; Peter Cheng; Wilina Lim; Peter Horby; Jeremy Farrar
Journal:  N Engl J Med       Date:  2004-02-25       Impact factor: 91.245

10.  Human disease from influenza A (H5N1), Thailand, 2004.

Authors:  Tawee Chotpitayasunondh; Kumnuan Ungchusak; Wanna Hanshaoworakul; Supamit Chunsuthiwat; Pathom Sawanpanyalert; Rungruen Kijphati; Sorasak Lochindarat; Panida Srisan; Pongsan Suwan; Yutthasak Osotthanakorn; Tanakorn Anantasetagoon; Supornchai Kanjanawasri; Sureeporn Tanupattarachai; Jiranun Weerakul; Ruangsri Chaiwirattana; Monthira Maneerattanaporn; Rapol Poolsavathitikool; Kulkunya Chokephaibulkit; Anucha Apisarnthanarak; Scott F Dowell
Journal:  Emerg Infect Dis       Date:  2005-02       Impact factor: 6.883

View more
  2 in total

Review 1.  Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.

Authors:  Man Wang; Shuai Jiang; Yefu Wang
Journal:  Bioengineered       Date:  2016-04       Impact factor: 3.269

2.  High-Titre Neutralizing Antibodies to H1N1 Influenza Virus after Mouse Immunization with Yeast Expressed H1 Antigen: A Promising Influenza Vaccine Candidate.

Authors:  Edyta Kopera; Konrad Zdanowski; Karolina Uranowska; Piotr Kosson; Violetta Sączyńska; Katarzyna Florys; Bogusław Szewczyk
Journal:  J Immunol Res       Date:  2019-01-08       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.